Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing
07:20pm, Friday, 21'st Mar 2025
Ginkgo Bioworks Holdings, Inc. (DNA) closed the most recent trading day at $7.27, moving +1.39% from the previous trading session.
Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed compreh
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
10:36am, Friday, 14'th Mar 2025
The heavy selling pressure might have exhausted for Ginkgo Bioworks (DNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street anal
Long-lasting in vivo antibody production: DMAb levels remained stable for 72 weeks in all participants (n=24) who have reached that timepoint No anti-drug antibodies (ADA): no immune rejection of the
Applied DNA Announces 1-For-50 Reverse Stock Split Effective March 14, 2025
08:00am, Wednesday, 12'th Mar 2025
STONY BROOK, NY / ACCESS Newswire / March 12, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec
VW's cheapest EV will have Rivian DNA and who is bidding for Canoo's assets
01:05pm, Thursday, 06'th Mar 2025
Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. Sign up here for free — just click TechCrunch Mobility!
Resilience is part of our DNA, says Merck KGaA CEO
01:00pm, Thursday, 06'th Mar 2025
Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering pro
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 05'th Mar 2025
Ginkgo Bioworks (DNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WuXi Biologics Launches EffiX™ Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production
07:30pm, Monday, 03'rd Mar 2025
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system.
Ginkgo Bioworks: Revenue Struggles Continue
10:29am, Thursday, 27'th Feb 2025
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping si
2025 Is Make Or Break For Ginkgo Bioworks
06:19am, Thursday, 27'th Feb 2025
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless G
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
08:10am, Wednesday, 26'th Feb 2025
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
08:05am, Wednesday, 26'th Feb 2025
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
09:22pm, Tuesday, 25'th Feb 2025
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kell
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Misses Revenue Estimates
07:31pm, Tuesday, 25'th Feb 2025
Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $3.60 per share a year ago.
